Oramed Pharmaceuticals - ORMP Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $22.50
  • Forecasted Upside: 981.73%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.08
▲ +0.01 (0.48%)

This chart shows the closing price for ORMP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oramed Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ORMP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ORMP

Analyst Price Target is $22.50
▲ +981.73% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Oramed Pharmaceuticals in the last 3 months. The average price target is $22.50, with a high forecast of $35.00 and a low forecast of $3.00. The average price target represents a 981.73% upside from the last price of $2.08.

This chart shows the closing price for ORMP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 polled investment analysts is to hold stock in Oramed Pharmaceuticals. This rating has held steady since October 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/8/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/17/2023HC WainwrightDowngradeBuy ➝ NeutralLow
1/13/2023Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
1/12/2023Canaccord Genuity GroupDowngradeBuy ➝ Hold$30.00 ➝ $3.00N/A
12/15/2022HC WainwrightReiterated RatingBuyLow
11/16/2022Alliance Global PartnersLower Target$35.00Low
3/17/2022HC WainwrightReiterated RatingBuy$32.00High
2/18/2022Cantor FitzgeraldInitiated CoverageOverweight$20.00Low
11/29/2021HC WainwrightReiterated RatingBuy$17.00 ➝ $32.00High
11/9/2021Alliance Global PartnersBoost TargetBuy$25.00 ➝ $40.00Low
11/2/2021AegisBoost TargetBuy$20.00 ➝ $35.00High
6/8/2021AegisBoost TargetBuy$12.00 ➝ $20.00Low
4/27/2021Alliance Global PartnersBoost TargetBuy$11.00 ➝ $25.00Medium
2/15/2021AegisReiterated RatingBuyHigh
2/9/2021National SecuritiesInitiated CoverageBuyLow
1/27/2021AegisBoost TargetBuy$6.00 ➝ $12.00Low
12/3/2020Alliance Global PartnersInitiated CoverageBuy$11.00High
7/13/2020HC WainwrightReiterated RatingBuy$16.00 ➝ $17.00High
6/22/2020HC WainwrightReiterated RatingBuy$20.00 ➝ $16.00Medium
6/2/2020AegisReiterated RatingBuyLow
3/11/2020AegisInitiated CoverageBuy$5.50Medium
9/18/2019HC WainwrightSet TargetBuy$20.00Low
9/11/2019LADENBURG THALM/SH SHInitiated CoverageBuy$7.00 ➝ $7.00High
6/19/2019HC WainwrightReiterated RatingBuyLow
5/23/2019HC WainwrightSet TargetBuy$25.00Low
4/15/2019HC WainwrightReiterated RatingBuy$25.00Low
1/23/2019HC WainwrightSet TargetBuy$25.00Low
1/14/2019HC WainwrightSet TargetBuy$25.00Medium
12/12/2018HC WainwrightSet TargetBuy$25.00Low
10/9/2018HC WainwrightSet TargetBuy$25.00Medium
7/16/2018B. RileyDowngradeBuy ➝ NeutralLow
6/6/2018HC WainwrightSet TargetBuy$25.00Low
(Data available from 2/7/2018 forward)

News Sentiment Rating

-0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/11/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/10/2022
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/10/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2022
  • 5 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/9/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/8/2023
  • 0 very positive mentions
  • 6 positive mentions
  • 6 negative mentions
  • 3 very negative mentions
2/7/2023

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 6 negative mentions
  • 3 very negative mentions
Oramed Pharmaceuticals logo
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.
Read More

Today's Range

Now: $2.08
Low: $1.99
High: $2.10

50 Day Range

MA: $7.02
Low: $1.93
High: $13.10

52 Week Range

Now: $2.08
Low: $1.81
High: $13.73

Volume

961,342 shs

Average Volume

3,711,506 shs

Market Capitalization

$81.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.86

Frequently Asked Questions

What sell-side analysts currently cover shares of Oramed Pharmaceuticals?

The following sell-side analysts have issued research reports on Oramed Pharmaceuticals in the last year: Alliance Global Partners, Canaccord Genuity Group Inc., Cantor Fitzgerald, HC Wainwright, and StockNews.com.
View the latest analyst ratings for ORMP.

What is the current price target for Oramed Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Oramed Pharmaceuticals in the last year. Their average twelve-month price target is $22.50, suggesting a possible upside of 981.7%. Alliance Global Partners has the highest price target set, predicting ORMP will reach $35.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $3.00 for Oramed Pharmaceuticals in the next year.
View the latest price targets for ORMP.

What is the current consensus analyst rating for Oramed Pharmaceuticals?

Oramed Pharmaceuticals currently has 3 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ORMP, but not buy more shares or sell existing shares.
View the latest ratings for ORMP.

What other companies compete with Oramed Pharmaceuticals?

How do I contact Oramed Pharmaceuticals' investor relations team?

Oramed Pharmaceuticals' physical mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The biotechnology company's listed phone number is (844) 967-2633 and its investor relations email address is [email protected] The official website for Oramed Pharmaceuticals is www.oramed.com. Learn More about contacing Oramed Pharmaceuticals investor relations.